Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Gain Therapeutics Inc. Common Stock
GANX | US
1.83
USD-0.13
-6.63%
GANX | US
About Gain Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.83
Open
1.91
High
1.92
Low
1.82
Gain Therapeutics Inc. a biotechnology company researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites restore protein folding and treat disease. Its lead product candidate includes GT-02287 for the treatment of GBA1 Parkinson's disease. In addition the company is developing structurally targeted allosteric regulator candidates to treat various diseases including Morquio B GM1 gangliosidosis (GM1) neuronopathic Gaucher disease GBA1 Parkinson's Krabbe and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics Inc. was founded in 2017 and is headquartered in Bethesda Maryland.
View LessGANX | US
Risk
73.0
Sharpe
-0.01
Luna's Score
43/100
Recommendation
Sell
Luna says (GANX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
92.7%1 month
73.0%3 months
96.7%6 months
125.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
6.00
Debt to equity
0.07
Debt to assets
0.04
Ent. to EBITDA
-1.55
Ent. to rev.
138.34
PEG
-
Other Fundamentals
EBITDA
-21.82M
MarketCap
46.73M
MarketCap(USD)
46.73M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-188.83
Short ratio
1.97
Short perc.
2.69
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.52
Range1M
0.52
Range3M
1.54
Volumes: Market Activity
Rel. volume
1.34
Price X volume
1.62M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.55 | - | Cheaper |
| Ent. to Revenue | 138.34 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.00 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 96.73 | - | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 46.73M | - | Emerging |
